Mammoth Biosciences Stock
HealthTechLooking to sell Mammoth Biosciences stock or options?
Mammoth Biosciences, a biotechnology company, is focused on developing long-term curative therapies and decentralized precision diagnostics. Leveraging its proprietary ultracompact proteins for in vivo gene editing in hard-to-reach tissues, the company utilizes nuclease applications such as base editing, gene writing, and epigenetic editing, enabling healthcare professionals to enhance patient outcomes.
University of California, Decheng Capital, Tachyon Ventures, Tectonic Capital, Regeneron Pharmaceuticals, K50 Ventures, Berkeley Frontier Fund, Plum Alley Investments, Boom Capital Ventures, Sixth Street Partners, Wireframe Ventures, Redmile Group, DHVC, Amazon.com, Mission Bay Capital, Berkeley, 8VC, Kairos HQ, Mission BioCapital, Brook Byers, Plug and Play Tech Center, Verily Life Sciences, Foresite Capital, California Innovation Fund, Senator Investment Group.